ADVANCE ONLINE PUBLICATION

RESEARCH HIGHLIGHTS

EMP1⁺ tumor cells drive metastatic relapse

Oscar E. Villarreal , Scott Kopetz

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
* Correspondence: Scott Kopetz(skopetz@mdanderson.org)

Disease relapse after surgical management in patients with early-stage colorectal cancer remains a significant clinical challenge due to its high incidence and lack of efficacious therapeutic interventions. In a recent study, Canellas-Socias et al. demonstrate that EMP1+ tumor cells are responsible for metastatic relapse and can be targeted by neoadjuvant immunotherapy to improve outcomes.

https://doi.org/10.1038/s41422-022-00769-w

FULL TEXT | PDF

Browse 252